Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

CTXR holding history

Citius Pharmaceuticals, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

CTXR overviewAll 13F holders of CTXRFull Q2 2026 holdings

Shares (Q2 2026)
26,335
Value
$15.9K
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of CTXR by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202626,335$15.9K<0.1%−28,690−52.1%ReducedHolders
Q1 202655,025$49.5K<0.1%−21,411−28.0%ReducedHolders
Q4 202576,436$59.4K<0.1%+50,523+195.0%AddedHolders
Q3 202525,913$32.1K<0.1%−167,014−86.6%ReducedHolders
Q2 2025192,927$306.8K<0.1%+125,712+187.0%AddedHolders
Q1 202567,215$100.2K<0.1%+39,648+143.8%AddedHolders
Q4 202427,567$110.3K<0.1%+27,543+113,813.2%AddedConverted for a 1-for-25 splitHolders
Q3 2024605$303<0.1%−62,174−99.0%ReducedHolders
Q2 202462,779$36.7K<0.1%−71,834−53.4%ReducedHolders
Q1 2024134,613$120.7K<0.1%−2,900−2.1%ReducedHolders
Q4 2023137,513$104.0K<0.1%+39,489+40.3%AddedHolders
Q3 202398,024$67.0K<0.1%+26,896+37.8%AddedHolders
Q2 202371,128$85.4K<0.1%+70,762+19,333.9%AddedHolders
Q1 2023366$428<0.1%+366NewHolders
Q3 20220$00.0%−1,132−100.0%Sold outHolders
Q2 20221,132$1.00K<0.1%−23,099−95.3%ReducedHolders
Q1 202224,231$43.0K<0.1%−73,461−75.2%ReducedHolders
Q4 202197,692$150.0K<0.1%+40,930+72.1%AddedHolders
Q3 202156,762$115.0K<0.1%+9,669+20.5%AddedHolders
Q2 202147,093$164.0K<0.1%−65,900−58.3%ReducedHolders
Q1 2021112,993$201.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.